Multicenter trial for the safety of rifaximin on hepatic encephalopathy

Multicenter trial for the safety of rifaximin on hepatic encephalopathy - The study of the safety of rifaximin

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028637

Enrollment

150

Registered

2018-01-01

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic encephalopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)>20 years old 2)The patients obtained the consent 3)> 12 months of suvival periods 4) a)Child Pugh score <=9 b)T-Bil <5.0 mg/dL c)AST and ALT <=6 times of the facilities standards

Exclusion criteria

Exclusion criteria: 1)The impossible of oral intake 2)The pharmacokinetics is changed for patient's condition 3)The necessary medicine change the pharmacokinetics of rifaximin 4)The pregnancy and lactating 5)The allergy of rifaximin 6)The outcome evaluation is difficult for patient's condition 7)Suffering hepatoma 8)The execution plan of achievement is difficult

Design outcomes

Primary

Measure	Time frame
Long-term safety.	—

Secondary

Measure	Time frame
Improvement of hepatic encephalopathy Depression of occurrence	—

Countries

Japan

Contacts

Public ContactKosuke Kaji

Nara medical unversity 3rd departemnt of interanal medicine

kajik@naramed-u.ac.jp0744-22-3051

Outcome results